Abstract
Introduction Monitoring of renal function after kidney transplantation (KT) is performed by measuring serum creatinine (SCr), urine volumes (UV), and glomerular filtration rate (GFR). Other methods based on oxygen metabolism such as the renal venous oxygen pressure (PrvO2) may be useful. We aimed to explore the correlation between PrvO2 and SCr, UV, and GFR five days after KT (SCr5, UV5, and GFR5, respectively).
Methods We conducted a prospective cohort study in adult patients scheduled for living-donor KT. A venous blood sample was taken from the renal vein after declamping the renal artery and blood gas determinations were made. Correlation analyses between PrvO2 and SCr5, UV5, and GFR5, were done by calculating the Spearman correlation coefficient together with generalized linear models (GLM). A Spearman correlation analysis was performed between the percentage decrease in SCr (%ΔSCr) and PrvO2. A GLM was also performed to determine the association of PrvO2 with slow graft function (SGF).
Results 42 patients were included; 66.7% were men, and the median age was 31 years (IQR: 27-43.5). PrvO2 was negatively correlated with SCr5 (ρ=-0.53, p=0.003), and positively correlated with GFR5 (ρ=0.49, p=0.001) and %ΔSCr (ρ=0.47, p=0.002). A higher PrvO2 was associated with an increase in GFR in univariable (β=1.24, 95%CI: 0.56-1.93, p=0.001) and multivariable (β=1.24, 95%CI: 0.53-1.94, p=0.001) analyses. No association was found between PrvO2 and SGF.
Conclusion PrvO2 could be used to monitor renal function in the first 5 days following related living-donor KT given its good correlation with SCr and GFR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics and Research Committee of the Instituto Mexicano del Seguro Social gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Authors’ surnames and initials: Escarramán-Martínez (DE-M), Fernández-Bravo (MF-B), Kammar-García (AK-G), Guerrero-Gutiérrez (MAG-G), Meza-Comparán (HDM-C), Mancilla-Galindo (JM-G), Sánchez-Díaz (JSS-D), Cendejas-Ríos (EC-R), Escorza-Molina (CAE-M), Noriega-Salas (LN-S), Bernaldez-Gómez (GB-G).
Address reprint requests to: Diego Escarramán-Martínez MD, MSc. Departamento de Anestesiología, Centro Médico Nacional Hospital de Especialidades “La Raza”, Instituto Mexicano del Seguro Social, Mexico City, Mexico. E-mail: diego-piloto{at}hotmail.com.
Data Availability
The data that support the findings of this study are openly available in the Harvard Dataverse Repository at https://doi.org/10.7910/DVN/VBCKWO
